The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...